1/16
04:01 pm
crvs
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Low
Report
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
1/12
07:05 am
crvs
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
Low
Report
Retail investors account for 39% of Corvus Pharmaceuticals, Inc.'s (NASDAQ:CRVS) ownership, while institutions account for 39% [Yahoo! Finance]
1/5
09:15 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference [Yahoo! Finance]
1/5
08:30 am
crvs
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Medium
Report
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
12/11
10:04 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
12/8
10:30 am
crvs
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
Medium
Report
Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial
11/9
10:49 am
crvs
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
Medium
Report
Corvus Pharmaceuticals: Moving Slowly Forward [Seeking Alpha]
11/4
04:13 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/4
04:01 pm
crvs
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
Low
Report
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
11/3
09:02 am
crvs
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Low
Report
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
10/31
07:30 am
crvs
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Medium
Report
Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
10/29
10:07 am
crvs
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $13.00 price target on by analysts at Mizuho.
Low
Report
Corvus Pharmaceuticals (NASDAQ:CRVS) was given a new $13.00 price target on by analysts at Mizuho.
10/28
04:01 pm
crvs
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Low
Report
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025